CalciMedica Says Auxora Phase 2 Trial May Continue Dosing After FDA Review

MT Newswires Live06-24

CalciMedica (CALC) said Wednesday the US Food and Drug Administration completed its review of a protocol amendment and interim safety data from the phase 2 KOURAGE trial of Auxora without comments or questions, and the company said it may continue dosing patients in the study.

The trial is evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure.

The phase 2 KOURAGE trial of Auxora was paused in January 2026 after an IDMC flagged a mortality imbalance, with CalciMedica saying no drug-related toxicity was found and that baseline disease severity differences were identified.

CalciMedica said it submitted protocol amendments and a safety review of 107 patients, noting that adverse events were consistent with prior experience and not considered drug-related.

The company added it expects FDA feedback on a potential pivotal program in acute pancreatitis in the third quarter of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645890326?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 19:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645890326","market":"sg","top_or_hot":-1,"title":"CalciMedica Says Auxora Phase 2 Trial May Continue Dosing After FDA Review","media":"MT Newswires Live","content":"<html><body><p> CalciMedica (CALC) said Wednesday the US Food and Drug Administration completed its review of a protocol amendment and interim safety data from the phase 2 KOURAGE trial of Auxora without comments or questions, and the company said it may continue dosing patients in the study.</p><p>The trial is evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure.</p><p>The phase 2 KOURAGE trial of Auxora was paused in January 2026 after an IDMC flagged a mortality imbalance, with CalciMedica saying no drug-related toxicity was found and that baseline disease severity differences were identified.</p><p>CalciMedica said it submitted protocol amendments and a safety review of 107 patients, noting that adverse events were consistent with prior experience and not considered drug-related.</p><p>The company added it expects FDA feedback on a potential pivotal program in acute pancreatitis in the third quarter of 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CalciMedica Says Auxora Phase 2 Trial May Continue Dosing After FDA Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCalciMedica Says Auxora Phase 2 Trial May Continue Dosing After FDA Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-24 19:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CalciMedica (CALC) said Wednesday the US Food and Drug Administration completed its review of a protocol amendment and interim safety data from the phase 2 KOURAGE trial of Auxora without comments or questions, and the company said it may continue dosing patients in the study.</p><p>The trial is evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure.</p><p>The phase 2 KOURAGE trial of Auxora was paused in January 2026 after an IDMC flagged a mortality imbalance, with CalciMedica saying no drug-related toxicity was found and that baseline disease severity differences were identified.</p><p>CalciMedica said it submitted protocol amendments and a safety review of 107 patients, noting that adverse events were consistent with prior experience and not considered drug-related.</p><p>The company added it expects FDA feedback on a potential pivotal program in acute pancreatitis in the third quarter of 2026.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2645890326","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645890326","pubTimestamp":1782301621,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CalciMedica (CALC) said Wednesday the US Food and Drug Administration completed its review of a protocol amendment and interim safety data from the phase 2 KOURAGE trial of Auxora without comments or ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","CALC":"CALCIMEDICA","BK4585":"ETF&股票定投概念","LABU":"三倍做多标普生物-Direxion","BK4007":"制药"},"translate_title":"CalciMedica表示Auxora 2期试验可能在FDA审查后继续给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CALC":1,"LABU":1.5},"content_text":"CalciMedica (CALC) said Wednesday the US Food and Drug Administration completed its review of a protocol amendment and interim safety data from the phase 2 KOURAGE trial of Auxora without comments or questions, and the company said it may continue dosing patients in the study.The trial is evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure.The phase 2 KOURAGE trial of Auxora was paused in January 2026 after an IDMC flagged a mortality imbalance, with CalciMedica saying no drug-related toxicity was found and that baseline disease severity differences were identified.CalciMedica said it submitted protocol amendments and a safety review of 107 patients, noting that adverse events were consistent with prior experience and not considered drug-related.The company added it expects FDA feedback on a potential pivotal program in acute pancreatitis in the third quarter of 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645890326","isCrawlerRequest":true}